Skip to content
Buy This GLP
← Research
Evidence

Do Teenagers Stay on GLP-1 Drugs?

U.S. claims, Danish prescription records and the STEP TEENS trial each measured continued treatment differently.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Two measures of continued GLP-1 treatmentU.S. pediatric patients20.3%Persistent refill pattern among 1,139 patientsDanish adolescents ages 12–1754%Estimated prescription coverage at one yearThe studies used different definitions.

Studies of how long people stay on GLP-1 treatment can count uninterrupted refills, a prescription covering a particular date or completion of a trial. Those definitions help explain why the reported numbers for adolescents differ.

What the U.S. claims study measured

Researchers followed a cohort of 1,139 pediatric patients and 201,229 adults with obesity and no diabetes using U.S. commercial insurance claims from 2021 to 2023. They grouped people by monthly prescription coverage over the year after starting treatment. Among pediatric patients, 20.3% fell into the persistent-user group, compared with 30.7% of adults [1]. Others had different refill patterns, including intermittent coverage. The study could not determine which doses people took or why they had gaps.

What the Danish prescription registry found

At one year, 54% of the adolescents ages 12 to 17 and 37% of the young adults ages 18 to 24 had estimated prescription coverage. That allowed for a gap followed by a restart. Across both age groups, 38% had estimated coverage and 22% had stayed on treatment without a gap under the study definition [2]. The Danish study included multiple drugs and some patients with diabetes, so its rates cannot be directly compared with the U.S. data.

What happened in STEP TEENS?

The review of lifestyle treatment and obesity medicines in teens compares weight outcomes across several treatment approaches. The claims studies above measured how long people kept filling prescriptions.

In STEP TEENS, 180 of 201 randomized participants completed 68 weeks of assigned treatment, about 90% in both the semaglutide and placebo groups [3]. Both groups received lifestyle support and followed the study schedule. Completion in this setting does not establish how many adolescents would keep filling prescriptions in routine care.

If prescription access, side effects or treatment goals change, families can discuss next steps with the clinician managing the adolescent’s care.

Frequently asked

How many teens are still taking a GLP-1 after one year?
In Denmark, 54% of ages 12 to 17 had estimated prescription coverage at one year, even if they had interrupted treatment earlier. A U.S. study put 20.3% of pediatric patients into a persistent-refill group over 12 months. The two studies used different measures.
Do prescription claims show whether someone took every dose?
Claims show prescription fills. Researchers use them to estimate treatment coverage, but the records do not verify individual doses.

Sources

  1. [1] Huang W, et al. (2026). Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity Diabetes, Obesity & Metabolism. PMID 42755139
  2. [2] Kildegaard H, et al. (2026). Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025 Obesity. PMID 42252120
  3. [3] Weghuber D, et al. (2022). Once-Weekly Semaglutide in Adolescents with Obesity New England Journal of Medicine. PMID 36322838

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence